BioSpace News Archive

The wave of biopharma companies going public continues with two more companies setting sights on publicly trading on a stock exchange. Reneo Pharmaceuticals and VectivBio will both begin trading on the Nasdaq this week.

Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced that it will issue a press release reporting its financial results for the full year ended December 31, 2020, on Thursday, April 15, 2021, and will host a conference call to discuss these results at 8 a.m. EDT that day.

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the appointment of Yan Zhang to the role of CEO.

Studies to evaluate liver and pancreatic cancers with SD-101, an investigational TLR9 agonist, in combination with checkpoint inhibition immunotherapy

Phase 3 Data from KEYNOTE-564 to be Presented at Upcoming Medical Meeting and Submitted to Regulatory Authorities

Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., founder, president, and CEO of Akouos, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14 at 4:30 p.m. ET.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the 20th Annual Needham Virtual Healthcare Conference.

CareDx, Inc. announced that they have launched a fully-functional next generation sequencing HLA typing service lab in Stockholm, Sweden to support companies in research and academic studies working on HLA applications in vaccine and drug development as well as disease association studies.

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab) Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and healthcare sustainability

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference